These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 12492201

  • 1. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K, DeGarmo RG, Jhingran P, Bagby B, Decker C, Markowitz M, Carter E, Bobbitt W, Dahdul A, DeCastro E, Gringeri L, Johanson J, Levinson L, Mula G, Poleynard G, Stoltz RR, Truesdale R, Young D, Lotronex Investigator Team.
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ.
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [Abstract] [Full Text] [Related]

  • 3. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P, Carter E, Lotronex Investigator Team.
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 6. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW.
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [Abstract] [Full Text] [Related]

  • 7. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [Abstract] [Full Text] [Related]

  • 8. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
    Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM.
    Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.
    Arch Intern Med; 2001 Jul 23; 161(14):1733-40. PubMed ID: 11485506
    [Abstract] [Full Text] [Related]

  • 10. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 11. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA.
    Am J Gastroenterol; 2008 May 15; 103(5):1217-25. PubMed ID: 18477346
    [Abstract] [Full Text] [Related]

  • 12. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.
    Bellini M, Rappelli L, Blandizzi C, Costa F, Stasi C, Colucci R, Giannaccini G, Marazziti D, Betti L, Baroni S, Mumolo MG, Marchi S, Del Tacca M.
    Am J Gastroenterol; 2003 Dec 15; 98(12):2705-11. PubMed ID: 14687821
    [Abstract] [Full Text] [Related]

  • 13. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
    Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.
    Clin Gastroenterol Hepatol; 2004 Aug 15; 2(8):675-82. PubMed ID: 15290660
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of treatment continuation with alosetron by IBS-D severity criteria.
    Nicandro JP, Shin P, Chuang E.
    Curr Med Res Opin; 2012 Mar 15; 28(3):449-56. PubMed ID: 22313141
    [Abstract] [Full Text] [Related]

  • 15. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
    Bleser S.
    Curr Med Res Opin; 2011 Mar 15; 27(3):503-12. PubMed ID: 21208139
    [Abstract] [Full Text] [Related]

  • 16. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
    Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, Mangel AW.
    Aliment Pharmacol Ther; 2008 Jan 15; 27(2):197-206. PubMed ID: 17973974
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY, Lu CL, Chen CY, Luo JC.
    J Gastroenterol Hepatol; 2007 Dec 15; 22(12):2266-72. PubMed ID: 17559369
    [Abstract] [Full Text] [Related]

  • 18. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH.
    Expert Rev Gastroenterol Hepatol; 2010 Feb 15; 4(1):13-29. PubMed ID: 20136586
    [Abstract] [Full Text] [Related]

  • 19. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
    Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM.
    Am J Gastroenterol; 2001 Sep 15; 96(9):2671-6. PubMed ID: 11569693
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW.
    Lancet; 2000 Mar 25; 355(9209):1035-40. PubMed ID: 10744088
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.